Polymorphs of LNnT

Patent metadata

Field	Value
Publication number	US-9815862-B2
Application number	US-201314653086-A
Country	US
Kind code	B2
Filing date	Dec 18, 2013
Priority date	Dec 18, 2012
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

A crystalline LNnT polymorph IV, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16, 15.41, 39.14, 23.77, 7.77 and 31.15 2Θ angles, and a crystalline LNnT polymorph V, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15, 10.26, 19.68, 26.06, 20.61 and 1 1.89 2Θ angles, are provided.

First claim

The invention claimed is:

1. A crystalline LNnT polymorph IV, wherein the crystalline LNnT polymorph IV displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16 2Θ, 15.41 2Θ, 39.14 2Θ, 23.77 2Θ, and 7.77 2Θ.

2. The crystalline LNnT polymorph IV of claim 1 , wherein the crystalline LNnT polymorph IV is substantially pure.

3. The crystalline LNnT polymorph IV of claim 1 , wherein the crystalline LNnT polymorph IV is substantially free from organic solvent.

4. The crystalline LNnT polymorph IV of claim 1 for use as a pharmaceutical agent.

5. A pharmaceutical composition comprising the crystalline LNnT polymorph IV of claim 1 and one or more pharmaceutically acceptable carriers.

6. A nutritional formulation comprising the crystalline LNnT polymorph IV of claim 1 .

7. The nutritional formulation of claim 6 , wherein the nutritional formulation is an infant formula.

8. The nutritional formulation of claim 6 , wherein the nutritional formulation is a food supplement.

9. The food supplement of claim 8 , wherein the food supplement is a digestive health functional food.

10. The crystalline LNnT polymorph IV of claim 1 , wherein the crystalline LNnT polymorph IV displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16 2Θ, 15.41 2Θ, 39.14 2Θ, 23.77 2Θ, 7.77 2Θ, and 31.15 2Θ.

11. A crystalline LNnT polymorph V, wherein the crystalline LNnT polymorph V displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15 2Θ, 10.26 2Θ, 19.68 2Θ, 26.06 2Θ, and 20.61 2Θ.

12. A method for producing the crystalline LNnT polymorph IV of claim 1 , wherein an aqueous solution of greater than 25 w/w % LNnT is stored at 2-25° C.

13. The crystalline LNnT polymorph IV of claim 11 , wherein the crystalline LNnT polymorph V displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15 2Θ, 10.26 2Θ, 19.68 2Θ, 26.06 2Θ, 20.61 2Θ, and 11.89 2Θ.

14. The crystalline LNnT polymorph V of claim 11 , wherein the crystalline LNnT polymorph V is substantially pure.

15. The crystalline LNnT polymorph V of claim 11 , wherein the crystalline LNnT polymorph V is substantially free from organic solvent.

16. The crystalline LNnT polymorph V of claim 11 for use as a pharmaceutical agent.

17. A pharmaceuticalcomposition comprising the crystalline LNnT polymorph V of claim 11 and one or more pharmaceutically acceptable carriers.

18. A nutritional formulation comprising the crystalline LNnT polymorph V of claim 11 .

19. A method for producing the crystalline LNnT polymorph V of claim 11 , wherein the crystalline LNnT polymorph IV of claim 1 is dried under vacuum at 40-60° C.

Assignees

• Glycom As

Inventors

• Podányi Benjámin
• Dekany Gyula

Classifications

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A23L33/40

  Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title

• C07H15/12 Primary

  attached to a nitrogen atom of the saccharide radical · CPC title

• C07H13/04

  having the esterifying carboxyl radicals attached to acyclic carbon atoms · CPC title